Efficacy and safety of finerenone in non-diabetic chronic kidney disease: a systematic review and meta-analysis
International Urology and Nephrology · 05.11.2026
DOI: 10.1007/s11255-026-05442-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Urology and Nephrology, online erschienen am 05.11.2026. Verfasst von Abbas Khan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Khyber Medical College, Peshawar, Pakistan. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), reduces composite kidney, and cardiovascular endpoints in diabetic CKD. Its efficacy and safety across non-diabetic CKD aetiologies remain uncharacterised in prior meta-analyses. METHODS: Four databases were searched to May 2026. RCTs and observational studies enrolling adults with non-diabetic CKD receiving finerenone were eligible. Two streams were used: Stream A (single-arm) and Stream B (comparative, finerenone vs. controls). The primary outcomes were eGFR slope/12-month change and proteinuria reduction; safety outcomes were hyperkalaemia, hypotension, adverse events, and discontinuation. Random-effects models (Hartung-Knapp), ROB-2, Newcastle-Ottawa Scale, GRADE, and TSA were applied. RESULTS: Nine studies (N = 2020) met eligibility, including two RCTs (the placebo-controlled FIND-CKD trial (n = 1584) and an open-label crossover pilot), alongside seven observational studies. Finerenone significantly slowed eGFR decline in the RCT (slope difference +0.70 mL/min/1.73m2/year, 95%CI 0.30-1.10; P < 0.001) and increased odds of a ≥ 30% proteinuria response roughly four-fold (pooled OR 3.99, 95% CI 1.91-8.30; P = 0.027). Two propensity-matched IgAN cohorts showed a 76.8% reduction in proteinuria versus controls (95% CI -81.1% to -72.6%; I2 = 0%). In single-arm analysis, 28.9% achieved a ≥ 50% proteinuria reduction. Hyperkalaemia was more frequent with finerenone (17.0% vs 13.3%; OR 1.34, 95% CI 1.02-1.76), though any adverse event did not differ (OR 1.15, 95% CI 0.67-1.99); pooled hyperkalaemia was 1.6%, hypotension 0.5%, discontinuation 0/258. CONCLUSIONS: In non-diabetic CKD, finerenone slows eGFR decline, supported by high-certainty evidence from FIND-CKD, and reduces proteinuria, with a modest rise in hyperkalaemia. These data support finerenone as a kidney-protective, proteinuria-lowering therapy, underscoring the need for potassium monitoring, and further trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Khyber Medical College, Peshawar, Pakistan.
- Department of Medicine, Khyber Girls Medical College, Peshawar, Pakistan.
- Department of Medicine, Shaikh Khalifa Bin Zayed Al Nahyan Medical & Dental College, Lahore, Pakistan.
- Department of Medicine, Bakhtawar Amin Medical and Dental College, Multan, Pakistan.
- Department of Medicine, Northwest School of Medicine, Peshawar, Pakistan.
- Department of Medicine, Hayatabad Medical Complex, Peshawar, Pakistan.
ORCID-Profile: Nour Aldin T Ahmed
Zitieren
APA
Khan, A., Sawaira, F. N. U., Ullah, G., Mahmood, H. A., Ameer, M. H., Abbas, A., Hassan, I., Javed, M., Ehsan, N., Ahmed, N. A. T., & Escalante, D. (2026). Efficacy and safety of finerenone in non-diabetic chronic kidney disease: a systematic review and meta-analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05442-4
Vancouver
Khan A, Sawaira FNU, Ullah G, Mahmood HA, Ameer MH, Abbas A, et al. Efficacy and safety of finerenone in non-diabetic chronic kidney disease: a systematic review and meta-analysis. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05442-4
BibTeX
@article{Khan2026,
author = {Khan, Abbas and Sawaira, F N U and Ullah, Gauhar and Mahmood, Hafiz Abad and Ameer, Muhammad Hassan and Abbas, Abdullah and Hassan, Irtaza and Javed, Mahnoor and Ehsan, Nimra and Ahmed, Nour Aldin T and Escalante, David},
title = {Efficacy and safety of finerenone in non-diabetic chronic kidney disease: a systematic review and meta-analysis},
journal = {International Urology and Nephrology},
year = {2026},
doi = {10.1007/s11255-026-05442-4}
}
EUVIMED